Interstitial lung diseases (ILDs) encompass a broad spectrum of conditions characterized by inflammation and fibrosis of the lung interstitium. This article provides a comprehensive overview of ILDs, focusing on their etiology, clinical presentation, diagnosis, and management.
ILDs can be idiopathic, related to systemic diseases, or due to occupational and environmental exposure. The most common idiopathic ILD is idiopathic pulmonary fibrosis (IPF), while connective tissue diseases often underlie systemic ILDs. Asbestosis, silicosis, and hypersensitivity pneumonitis are examples of exposure-related ILDs.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Physical examination may reveal crackles and clubbing. Advanced disease stages may result in respiratory failure.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs, demonstrating characteristic patterns such as reticulation, honeycombing, and ground-glass opacities. Pulmonary function tests often show a restrictive pattern. In certain cases, lung biopsy may be required for definitive diagnosis.
Management of ILDs is primarily focused on treating the underlying cause, slowing disease progression, and managing symptoms. Antifibrotic agents such as pirfenidone and nintedanib have shown promise in IPF. For other ILDs, immunosuppressive therapy may be beneficial. Lung transplantation is considered in severe cases.
In conclusion, ILDs are a heterogeneous group of diseases with diverse etiologies, but similar clinical and radiological features. Early recognition and appropriate management of these conditions can significantly improve patient outcomes, underscoring the importance of a thorough understanding of these diseases among healthcare professionals.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation